Vaccine News and Research

Latest Vaccine News and Research

Study identifies a promising new strategy for combating malaria

Researchers have discovered a promising new strategy for combating malaria, a mosquito-borne parasite that claims nearly a half-million lives each year.

22 Apr 2020

Have we found a new malaria vaccine?

A new study published in the journal Nature in April 2020 reports on a malaria protein antibody that appears to protect resistant children from severe disease, showing promise in the fight against malaria, a new study found. Almost 500,000 people die of malaria every year.

22 Apr 2020

Emergex partners with George Mason University for highly pathogenic RNA virus studies

Emergex Vaccines Holding Limited, a biotechnology company developing CD8+ priming set-point vaccines to prevent serious infectious diseases, today announced that it has entered into an agreement with the George Mason University, based in Virginia, in the United States.

22 Apr 2020

A first-in-human trial with promising MERS coronavirus vaccine

Over the past 20 years, coronaviruses have been responsible for large outbreaks, resulting in severe respiratory illness and a number of deaths.

22 Apr 2020

Nanoengineers are using plant virus to develop COVID-19 vaccine

Nanoengineers at the University of California San Diego are working on a COVID-19 vaccine using an unconventional candidate: a plant virus.

22 Apr 2020

Is hydroxychloroquine effective against COVID-19?

Following the emergence of a novel coronavirus in Wuhan, China, in the last month of 2019, it has spread globally to produce the first pandemic of the 21st century. The virus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has already affected over 2.5 million and killed more than 177,000 people as of April 22, 2020.

22 Apr 2020

Using community memory to figure out the incubation period for COVID-19

The COVID-19 epidemic that began at the end of 2019 in China’s Wuhan city has now spread to over 185 countries and territories, taking over 177,000 lives out of approximately 2.5 million reported cases. Without either a vaccine or a reliable cure at hand, public health authorities are stretched to contain the virus spread.

22 Apr 2020

PiCoVacc vaccine candidate for COVID-19 effective in animal trials

In a new study available on the bioRxiv preprint server, a group of researchers from China report on the pilot-scale production of a purified inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus vaccine candidate (PiCoVacc), shown to induce virus-specific neutralizing antibodies in rats, mice, and non-human primates.

21 Apr 2020

Researchers develop new 3D multicomponent dissolvable vaccine platform

In parallel to their current work on a potential coronavirus vaccine, researchers at the University of Pittsburgh School of Medicine have developed a new vaccine delivery system for vaccines using live or attenuated viral vectors: a finger-tip sized patch that contains 400 tiny needles, each just half of one millimeter.

21 Apr 2020

Malaysian researchers discover new Leptospira strain capable of infecting humans

Malaysian researchers have identified the two species of the Leptospira genus of bacteria responsible for most cases of leptospirosis in the country and discovered a new strain capable of infecting humans.

21 Apr 2020

Difference between flu and novel coronavirus disease

Both influenza and COVID-19 disease are caused by infectious respiratory agents and cause symptoms that can look quite similar. Coronaviruses cause both. So, what’s the difference?

21 Apr 2020

USPTO grants patent to TAU scientist for innovative coronavirus vaccine design

Researchers worldwide are racing at breakneck speed to develop potential vaccines and drugs to fight the novel coronavirus, SARS-Cov-2.

21 Apr 2020

Sino Biological Partners with Nanommune Inc. to Develop and Market a Novel Coronavirus Multiplex Serological Assay

Sino Biological, Inc. today announced a co-development agreement with Nanommune Inc., an Irvine, California based biotechnology company specializing in the development and application of multiplex array technology.

From Sino Biological Inc. 21 Apr 2020

The inside story of how the Bay Area got ahead of the COVID-19 crisis

Sunday was supposed to be a rare day off for Dr. Tomás Aragón after weeks of working around-the-clock.

21 Apr 2020

Scientists use genomics and bioinformatics to analyze blueprint of novel coronavirus

Australian researchers from the Commonwealth Scientific and Industrial Research Organization (CSIRO) have found a new way to decode the genome of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease. This approach could help in drug and vaccine development. Their work titled, "Supporting pandemic response using genomics and bioinformatics: a case study on the emergent SARS-CoV-2 outbreak," is published in the latest issue of the journal Transboundary and Emerging Diseases.

21 Apr 2020

CSIRO researchers unveil new approach to understand evolving SARS-CoV-2 virus strains

Researchers from CSIRO, Australia's national science agency, have unveiled a new approach to analyzing the genetic codes - or the blueprint - of the SARS-CoV-2 virus that causes COVID-19.

20 Apr 2020

New review confirms effectiveness of MMR, MMRV and MMR+V vaccines

New evidence published in the Cochrane Library today finds MMR, MMRV and MMR+V vaccines are effective and that they are not associated with increased risk of autism.

20 Apr 2020

Attitudes towards vaccination vary significantly across Europe

Researchers in France have reported findings resulting from a web-based survey called Vaccinoscopie 2019 that asked 1,500 parents across five European countries how they feel about and what they know about vaccination.

20 Apr 2020

Antibody detection for COVID-19 - promise and risks

Recently, several research groups emphasized how the pervasive screening for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies may prove pivotal in determining infection seroprevalence in a given population defining previous exposure, screening health care workers, but also identifying highly reactive individuals that may act as donors for the therapeutic use of their convalescent serum.

20 Apr 2020

EMBL-EBI and partners launch new COVID-19 Data Portal

EMBL's European Bioinformatics Institute and partners today launched the COVID-19 Data Portal, which enables the sharing and analysis of data related to the new coronavirus, SARS-CoV-2.

20 Apr 2020